Research at MSK Our research impact Research topics Core facilities & resources ...
How are new targeted therapies for specific genetic mutations improving lung cancer treatment? We are getting new targeted therapies approved every year for genes that were long thought to be ...
We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...
The Exercise Oncology Service brings together scientists and physiologists to study the effect of physical activity on cancer treatment and prognosis. For years, people with cancer and their doctors ...
MSK gastrointestinal medical oncologist Dr. Wungki Park led the early phase clinical trial of daraxonrasib for people with metastatic pancreatic cancer that had stopped responding to chemotherapy.
For people living with advanced triple-negative breast cancer (TNBC), a newly approved treatment may offer more time and a better quality of life. TNBC makes up about 10% to 20% of all breast cancers, ...
Thoracic oncologist Kathryn Arbour, MD, led the Phase 1/2 clinical trial of daraxonrasib at MSK for metastatic lung cancer. The drug was approved by the FDA for pancreatic cancer in August 2026 and Dr ...
Find a researcher or lab Education & training programs MSK Innovation MSK Commercialization Ecosystem ...
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient ...
2. There are now more cases of head and neck cancers than cervical cancers in America; HPV causes 70% of them, according to the CDC. “My doctor told me that tumors of the neck and throat were getting ...
MSK gastrointestinal medical oncologist Eileen O'Reilly, MD (left), led a very promising early phase clinical trial of the targeted RAS therapy daraxonrasib for people facing pancreatic cancer.
Research at MSK Our research impact Research topics Core facilities & resources ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results